Background: Norepinephrine transporters (NETs) terminate the neuronal transmission of norepinephrine, which is released from noradrenergic neurons. To investigate the interaction with NET, the authors examined the effects of short-and long-term treatment with anesthetics on the activity and mRNA level of NET.
THE anesthetic action induced by general anesthetics is a complex phenomenon. Its important component appears to be an alteration of synaptic transmission in the central nervous system. 1, 2 A large number of recent studies have led to the proposal that actions on postsynaptic neurotransmitter receptors or presynaptic neurotransmitter release account for the dominant central nervous system-depressant effects of anesthetics. 3, 4 On the other hand, several lines of evidence have shown that some anesthetics also interact with presynaptic transporters to alter the uptake of neurotransmitters. For example, anesthetics inhibit the uptake of ␥-aminobutyric acid, 5 dopamine, 6 and serotonin 7 by rat brain synaptosomes. It is well known that ketamine suppresses the uptake of norepinephrine by sympathetic neurons, 8 -10 which may explain its sympathetic stimulation. This evidence suggests that neurotransmitter transporters are also a target site for anesthetics.
Norepinephrine transporters (NETs) located in the presynaptic membranes of noradrenergic nerve terminals mediate the termination of neurotransmission by the reuptake of norepinephrine released into the extracellular milieu. 11 Human NET was the first NET cloned, and its mRNA was localized in the brainstem and adrenal gland. 12 Bönisch's group cloned bovine adrenal medullary NET and reported that its pharmacologic properties were similar to those of the NET in central and peripheral noradrenergic neurons. 13, 14 Bovine NET expression in adrenal medullary cells has been used as a model system to study the effect of drugs on NET in noradrenergic neurons. [15] [16] [17] Recently, we reported that ketamine inhibits [ 3 H]norepinephrine uptake via an interaction with NET at a site partly overlapping the binding site of desipramine, 17 a selective inhibitor of NET. In the present study, we further examine the effects of other intravenous anesthetics (propofol, thiamylal, and diazepam) on NET in cultured bovine adrenal medullary cells. Comparing present results with those for ketamine, we searched for a putative common site for intravenous anesthetics on the NET. We also studied the effects of long-term treatment with propofol on the [ 3 H]norepinephrine uptake, [ 3 H]desipramine binding, and mRNA level of NET.
Materials and Methods

Materials
Eagle's minimum essential medium (MEM) was obtained from Nissui Pharmaceuticals (Tokyo, Japan). Fetal calf serum, l-norepinephrine, pargyline hydrochloride, and l-ascorbic acid were obtained from Nacalai Tesque (Kyoto, Japan). Collagenase was obtained from Nitta Zerachin (Osaka, Japan 
Isolation and Culture of Adrenal Medullary Cells
Adrenal medullary cells were isolated from bovine adrenal medulla as described previously. 18 The cells were plated at 4 ϫ 10 6 cells per dish (Falcon, 35 mm) in Eagle's MEM containing 10% fetal calf serum, 60 g/ml aminobenzylpenicillin, 100 g/ml streptomycin, 0.3 g/ml amphotericin B, and 3.0 M cytarabine. 15 The cells were cultured in 5% CO 2 -95% air at 37°C and used for experiments between 2 and 4 days of culture.
[ 3 H]Norepinephrine Uptake by the Cells
Cultured cells (4 ϫ 10 6 per dish) were incubated at 37°C for 15 min in oxygenated Krebs-Ringer phosphate buffer containing 100 M pargyline, 100 M ascorbic acid, and 500 nM [ 3 H]norepinephrine in the presence or absence of propofol (0.1-300 M), thiamylal (3-1,000 M), or diazepam (3-1,000 M). Pargyline is a monoamine oxidase inhibitor that prevents the enzymatic decomposition of norepinephrine in the cells. Ascorbic acid is an antioxidant of norepinephrine. Krebs-Ringer phosphate buffer was composed of 154 mM NaCl, 5.6 mM KCl, 1.1 mM MgSO 4 , 2.2 mM CaCl 2 , 0.85 mM NaH 2 PO 4 , 2.15 mM Na 2 HPO 4 , and 10 mM glucose, adjusted to pH 7.4. For the kinetic analysis of [ 3 H]norepinephrine uptake, the cells were incubated with increasing concentrations (1-30 M) of [ 3 H]norepinephrine in the presence or absence of 100 M propofol, thiamylal, or diazepam. After incubation, the cells were rapidly washed four times with 1 ml ice-cold buffer and solubilized in 1 ml Triton X-100 (10%; Nacalai Tesque, Kyoto, Japan). The radioactivity in the solubilized cells was counted by a liquid scintillation counter (LSC-3500E; Aloka, Tokyo, Japan). Nonspecific uptake was determined in the presence of 10 M desipramine, and specific uptake was obtained by subtracting the nonspecific uptake from the total uptake. The desipramine-sensitive uptake was 92 Ϯ 3% (n ϭ 12) of the total uptake.
[ 3 H]Desipramine Binding to Plasma Membranes
Plasma membranes isolated from bovine adrenal medulla were prepared as described previously. 19 The binding of [ 3 H]desipramine was determined by incubation of membranes (10 g protein) suspended in buffer B (composition: 135 mM NaCl, 10 mM Tris-HCl (pH 7.4), 5 mM KCl, 1 mM MgSO 4 ) for 30 min at 25°C. The incubation medium (final volume, 250 l) contained [ 3 H]desipramine (2-24 nM), and in some experiments also contained propofol (0.1-300 M). After incubation, binding was terminated by the addition of 2 ml ice-cold buffer B and rapid filtration of the membrane suspension under vacuum through Whatman GF/C glass fiber filters (Whatman, Maidstone, United Kingdom). The filters were rapidly washed twice with 2 ml ice-cold buffer B and were placed in counting vials containing a scintillation cocktail. The radioactivity was counted in Aloka LSC-3500E. Nonspecific binding was determined in the presence of 10 M nisoxetine, a selective NET inhibitor, and specific binding was obtained by subtracting the nonspecific binding from the total binding.
Long-term Treatment of Cells with Propofol for [ 3 H]Norepinephrine Uptake
Cells were preincubated with or without propofol (1-30 M) for 6 -24 h. After preincubation, the cells were washed with 2 ml Eagle's MEM and stood for another 3 h in a culture chamber to completely wash out propofol. The cells were then incubated with [ 3 H]norepinephrine (500 nM) for 15 min, and [ 3 H]norepinephrine uptake by the cells was evaluated as previously described.
Long-term Treatment of Cells with Propofol for [ 3 H]Desipramine Binding
After treatment of cells with 10 M propofol for 12 h and subsequent washing with 1 ml MEM and standing for 1 h, cells were collected and crashed by a homogenizer (Ultra-Turrax T8; IKA Labortechnik, Staufen, Germany) for 60 s in a lysis buffer (10 mM Tris-HCl [pH 7.4], 2 mM MgCl 2 , 1 mM dithiothreitol, 1 mM phenylmethylsulphonyl fluoride) and centrifuged at 1,000g for 10 min at 4°C. The supernatant was centrifuged at 60,000g for 30 min. The final pellet containing plasma membranes was suspended in the binding buffer (50 mM Tris-HCl [pH 7.4], 300 mM NaCl, 5 mM KCl). 16 The protein of isolated plasma membranes was quantified by the method of Lowry et al. 20 The binding of [ 3 H]desipramine was determined by incubation of membranes (100 g protein) suspended in buffer B for 30 min at 25°C as described previously.
Assay of Norepinephrine Transporter mRNA Expression by Reverse Transcriptase-Polymerase Chain Reaction
Poly(A) ϩ RNA was isolated from control or propofoltreated cells by guanidine hydrochloride, ethanol fractionation, chloroform-isobutanol extraction, and oligo(dT) cellulose column separation as previously described. 21 The first-strand cDNA was synthesized from Poly(A) ϩ RNA using a first-strand cDNA synthesis kit (Amersham Pharmacia Biotech, Piscaway, NJ). The obtained cDNA was amplified by polymerase chain reaction. Each sample was assayed for NET and ␤-actin mRNAs using their specific primers. The sense and antisense primers for NET were 5Ј-CTGACCAGCACCAT-CAACTGT-3Ј and 5Ј-GTGAAGAGTTTCCGGTGTCGC-3Ј, and those for ␤-actin were 5Ј-TGGAGAAGAGCTAT-GAGCTGCCTG-3Ј and 5Ј-GTGCCACCAGACAGCACTGT-GTTG-3Ј, respectively. Polymerase chain reaction using primers for NET or ␤-actin and a Takara Ex Taq kit (Takara, Otsu, Japan) was conducted with an automatic thermal controller (PC-800; Astec, Fukuoka, Japan). The thermocycling conditions were as follows: 28 cycles of 94°C for 1 min, 62°C for 30 s, 72°C for 20 s for NET; and 20 cycles of 94°C for 15 s, 66°C for 15 s, 72°C for 30 s for ␤-actin. The resultant polymerase chain reaction products were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and visualized by GelStar Nucleic Acid Gel Stain (Takara, Otsu, Japan). Fluorescence intensity of the bands was quantified with a Fuluoroimage Analyzer (BAS 3000; Fujifilm, Tokyo, Japan).
Data Analysis
All values are expressed as mean Ϯ SD. Statistical analysis was conducted by one-way analysis of variance followed by a Dunnett t test for multiple comparisons in figure 7 , one-way analysis of variance followed by a Dunnett t test was used. Differences were considered as statistically significant at P less than 0.05.
Results
Effects of Intravenous Anesthetics on [ 3 H]Norepinephrine Uptake
Uptake of [ 3 H]norepinephrine was linearly related to cell density (0.2-4 ϫ 10 6 cells) and incubation time (10 -40 min). 17 Thus, the assay condition (4 ϫ 10 6 cells, 15 min) selected for the subsequent experiments was well within the linear range of [ 3 H]norepinephrine uptake. All anesthetics, including propofol, thiamylal, and diazepam, inhibited [ 3 H]norepinephrine uptake in a con- The inhibition curve appeared to be biphasic. When the Table 1 
Effect of Propofol on [ 3 H]Desipramine Binding to Plasma Membranes Isolated from Bovine Adrenal Medulla
. Effects of Various Intravenous Anesthetics on the Kinetic Parameters for [ 3 H]Norepinephrine Uptake
Effect of Long-term Treatment with Propofol on [ 3 H]Norepinephrine Uptake, [ 3 H]Desipramine Binding, and Norepinephrine Transporter mRNA Expression
Long-term treatment of cells with propofol caused time-(6 -24 h) and concentration (1-10 M)-dependent increases in [ 3 H]norepinephrine uptake (figs. 5A and 5B). In the assay of [ 3 H]desipramine binding, specific binding of [ 3 H]desipramine to the plasma membranes prepared from control and propofol-treated cells was saturable with increasing concentrations of [ 3 H]desipramine (2-24 nM; fig.6A ). Scatchard analysis showed that 10 M propofol produced a significant (P Ͻ 0.05) increase in the B max (control, 230 Ϯ 18 fmol/mg protein; propofol, 270 Ϯ 13 fmol/mg protein) without any change in the K d (control, 6.6 Ϯ 0.3 nM; propofol, 6.3 Ϯ 0.4 nM; fig. 6B ). In the assay of mRNA expression, polymerase chain reaction with NET primers and ␤-actin primers yielded single bands corresponding to approxi-mately 0.3-kb and 0.2-kb fragments, respectively ( fig. 7) . The band for NET mRNA was sequenced and found to be identical to the reported bovine NET 13 (data not shown). 
Discussion
We demonstrated that all the intravenous anesthetics used in this study inhibited [ 3 H]norepinephrine uptake by cultured adrenal medullary cells. The rank order of the potency to suppress [ 3 H]norepinephrine uptake was propofol, diazepam, and thiamylal. The peak plasma concentration of propofol was reported to be approximately 50 M after bolus administration. 24 However, the steady state free plasma concentration of propofol may not exceed 2 M because 98% binds to plasma proteins. In addition, taking protein binding into account, the clinically relevant concentrations of diazepam and thiopental are approximately 1 M 25 and 25 M, 3 respectively, and the plasma concentration of the latter is similar to that of thiamylal. 26 At these clinically relevant values of the control group at 6, 12, and  24 h were 1.3 ؎ 0.2, 1.2 ؎ 0.2, and 1 concentrations, propofol and probably thiamylal seem to inhibit NET function to a small but significant degree. As much as 80% of norepinephrine released from presynaptic terminals is believed to be physiologically reuptaken by the neurons, 27 terminating neurotransmission. Therefore, even a slight inhibition of NET activity by clinical concentrations of anesthetics may enhance neurotransmission.
. The effect of long-term treatment with propofol on [ 3 H]norepinephrine uptake. (A) Time course of preincubation with propofol (1 M) for [ 3 H]norepinephrine uptake. After preincubation with or without propofol for the period indicated, the cells were cultured for another 3 h in propofol-free medium and then incubated at 37°C for 15 min in the presence of [ 3 H]norepinephrine (500 nM). The
To address the site of action of propofol on NET, we examined the effects of propofol on the kinetic parameters of [ 1 and 4 ), suggesting that propofol affects the NET at two sites of action, such as high-and a lowaffinity sites. Further study is required to confirm this possibility.
Over the past 10 yr, there has been controversy over whether the site of substrate recognition is identical to that for tricyclic antidepressant binding on monoamine transporters. 28, 29 From recent molecular cloning and chimeric dopamine-norepinephrine transporter studies, the current prevailing hypothesis is that there are distinct regions within NET molecules that determine sub-strate recognition and translocation and antagonist affinity, but these regions may overlap each other. 9, 30, 31 In the present study, the noncompetitive kinetics of [ 3 H]norepinephrine uptake suggest that propofol interacts with NET at a different site from the norepinephrine recognition site. The competitive inhibition of [ 3 H]desipramine binding by propofol suggests that propofol acts directly on the desipramine binding site. Alternatively, propofol and desipramine may act at different sites on the NET that are allosterically coupled. Thus, a simple interpretation of these results is that propofol interacts with NET, which, in turn, may allosterically lead to a conformational change in the transporter that inhibits transporter function. We previously proposed that ketamine inhibits the transport of norepinephrine by interacting with a site that partly overlaps the desipramine binding site on NET. 17 Propofol inhibited [ 3 H]norepinephrine uptake in a manner very similar to that of ketamine. Taken together, our present results provide further evidence to support the hypothesis that in NET molecules there is a common region or areas in close proximity that are susceptible to some intravenous anesthetics. Further studies using various NET mutants produced by molecular techniques are required to determine the precise site of intravenous anesthetic action on NET.
Our findings explain some of the pharmacologic effects of intravenous anesthetics. For instance, intravenous anesthetics may enhance the action of exogenous or endogenous catecholamines. Indeed, propofol and thiamylal are reported to enhance epinephrine-induced arrhythmias in dogs. [32] [33] [34] Furthermore, evidence has emerged that the descending inhibitory system consists of noradrenergic neurons. 35 Tricyclic antidepressants, including desipramine, that selectively antagonize NET are used to treat the chronic pain that accompanies postherpetic neuralgia, diabetic neuropathy, cancer, and complex regional pain syndrome. 36 -38 Their antinociceptive effect is considered to arise partly from enhancing noradrenergic neurotransmission by inhibiting NET in the descending inhibitory system in the brain and spinal cord. 39 Our results raise the possibility that the inhibitory effects of intravenous anesthetics on NET activity during anesthesia have an antinociceptive action.
Propofol is sometimes administered for prolonged periods during surgery. We found that treatment of cells with clinically relevant concentrations of propofol increased the functional activity of NET and [ 3 H]desipramine binding sites. Presently, clinical significance of the phenomenon is not clear. It may be regarded as a compensatory action of propofol that normalizes the norepinephrine level at noradrenergic synapses during anesthesia.
In conclusion, intravenous anesthetics have a dual effect on NET function: short-term treatment produces inhibition, whereas long-term treatment causes up-regulation. Our findings indicate that NET is one of the target proteins of intravenous anesthetics and help to unveil the pharmacologic basis of this interaction for the better understanding of the various actions of intravenous anesthetics.
